Eroglu Erdal, Gokcil Zeki, Bek Semai, Ulas Umit H, Ozdag Mehmet F, Odabasi Zeki
GATA Medical Faculty Department of Neurology, Etlik-ANKARA, Turkey.
J Neurol Sci. 2008 Dec 15;275(1-2):113-6. doi: 10.1016/j.jns.2008.07.033. Epub 2008 Sep 9.
Subacute sclerosing panencephalitis (SSPE) is a rare infectious central nervous system disease with a poor prognosis. Nineteen patients, 18 males and one female, ranging in age from 18 to 22, mean 19.6+/-1.5 years with SSPE were evaluated. We treated 9 patients with oral isoprinosine and 10 patients with alpha-interferon plus oral isoprinosine and followed up for 16 to 160 months. Of the 9 patients treated with oral isoprinosine, 7 (77.7%) died, one stabilized, and one showed progression. Seven (70%) of 10 patients treated with alpha-interferon plus oral isoprinosine died, one showed progression, and stabilization was observed in two patients. Thus, we suggest that isoprinosine alone or in combination with intraventricular interferon did not change the prognosis in long-term follow-up periods.
亚急性硬化性全脑炎(SSPE)是一种罕见的中枢神经系统感染性疾病,预后较差。我们评估了19例年龄在18至22岁(平均19.6±1.5岁)的SSPE患者,其中18例男性,1例女性。我们对9例患者采用口服异丙肌苷治疗,10例患者采用α-干扰素联合口服异丙肌苷治疗,并随访16至160个月。在接受口服异丙肌苷治疗的9例患者中,7例(77.7%)死亡,1例病情稳定,1例病情进展。在接受α-干扰素联合口服异丙肌苷治疗的10例患者中,7例(70%)死亡,1例病情进展,2例病情稳定。因此,我们认为单独使用异丙肌苷或与脑室内干扰素联合使用在长期随访中并未改变预后。